Skip to main content

Health condition

Peripheral T-cell lymphoma, a rare group needing specialist care from day one.

A rare, aggressive group of non-Hodgkin lymphomas arising from mature T-cells. Careful subtyping and specialist haemato-oncology input shape every decision that follows.

Jump to treatment
A radiographer guides a patient onto the bed of an advanced 3 Tesla MRI scanner in a London imaging suite

Why trust this guide

  • 01

    Editorial team

    Written by our editorial team from the UK sources listed on each page.

  • 02

    Sourced from guidance

    Checked against NICE NG52 and peer-reviewed haemato-oncology sources you can see at the end.

  • 03

    Current for 2026

    Reflects modern UK practice for a rare and complex group of lymphomas, including specialist MDT pathways.

Key facts

Peripheral T-cell lymphoma at a glance.

The essentials, in plain English - what it is, the main subtypes, and how it's approached in UK specialist centres today.

  • What it is

    A rare, aggressive group of non-Hodgkin lymphomas arising from mature T-cells rather than B-cells.

  • Main subtypes

    PTCL-not otherwise specified (the most common), angioimmunoblastic T-cell lymphoma, and anaplastic large cell lymphoma.

  • Prognosis

    Generally worse than B-cell lymphomas, though outcomes vary considerably by subtype and fitness for transplant.

  • Typical presentation

    Widespread lymphadenopathy plus prominent B symptoms - fever, night sweats and weight loss - often at an advanced stage.

  • Core treatment

    CHOP-based combination chemotherapy, with upfront autologous stem cell transplant considered for eligible patients.

  • Where it is treated

    A specialist commissioned haemato-oncology MDT with specific T-cell lymphoma expertise, given the rarity and complexity.

Why this guide matters

Rare disease, high-stakes decisions.

PTCL is uncommon enough that most people have never heard of it before diagnosis. The three points below shape everything else on this page.

  • Subtyping changes the plan

    PTCL is not one disease - PTCL-NOS, angioimmunoblastic and anaplastic large cell lymphoma can behave and respond quite differently.

  • Chemotherapy alone often isn’t enough

    Outcomes with CHOP-based treatment alone are generally less favourable than for B-cell lymphomas, which is why transplant and trials feature early.

  • Rarity means specialist care matters

    A commissioned MDT with specific T-cell lymphoma expertise sees more of these cases than any single local team - and that experience counts.

How the diagnosis is made

From swollen nodes to a specialist plan.

The steps a UK haemato-oncology team will normally follow, in order - so you know what to expect and why each one matters.

  1. 01

    Assessing

    Node and symptom review

    Assessment of widespread lymphadenopathy alongside B symptoms - fever, night sweats and unexplained weight loss.

  2. 02

    Assessing

    Excision biopsy

    A full lymph node excision biopsy, not a needle sample, so architecture and cell populations can be properly assessed.

  3. 03

    Assessing

    Immunohistochemistry and molecular studies

    Detailed subtyping is essential given the complexity of T-cell lymphoma classification - this is where the exact subtype is confirmed.

  4. 04

    Confirming

    CT or PET-CT staging

    Full-body imaging to map nodal and extranodal disease and establish the stage before treatment starts.

  5. 05

    Confirming

    Bone marrow biopsy

    Checks for marrow involvement, which is common in this group and affects staging and treatment planning.

  6. 06

    Preparing

    Specialist MDT discussion

    Given the rarity and complexity, cases go to a commissioned haemato-oncology MDT with specific T-cell lymphoma expertise.

  7. 07

    Preparing

    Fitness and transplant assessment

    Assessment for eligibility for upfront autologous stem cell transplant in first remission, alongside a clinical trial discussion.

Typical timeline: biopsy to a specialist MDT plan within two to three weeks.

Symptoms

What peripheral T-cell lymphoma actually looks like.

Widespread nodal disease and prominent B symptoms are the hallmark. And the features that mean it's time to escalate.

  • Widespread lymphadenopathy

    Enlarged lymph nodes, often in multiple sites, and frequently more extensive than typical B-cell lymphoma at presentation.

  • Fever

    Recurrent or unexplained fever without an obvious infective source - one of the classic B symptoms.

  • Night sweats

    Drenching sweats overnight, often needing a change of nightclothes or bedding.

  • Unexplained weight loss

    Significant, unintentional weight loss - typically more than ten per cent of body weight over six months.

  • Skin involvement

    Some subtypes, particularly angioimmunoblastic disease, can present with rashes, itch or infiltrated plaques.

  • Hepatosplenomegaly

    Enlargement of the liver or spleen, sometimes found on examination or incidentally on imaging.

  • Advanced-stage disease at diagnosis

    PTCL is more likely than B-cell lymphoma to present at an advanced or aggressive stage from the outset.

  • Red flag - rapid systemic decline

    Fast-progressing systemic symptoms alongside marrow or organ involvement need urgent haemato-oncology assessment.

Treatment

How peripheral T-cell lymphoma is treated.

CHOP-based chemotherapy first, with transplant, targeted agents and trials shaping the path for many patients.

  • CHOP-based chemotherapy

    Combination chemotherapy is the standard first-line approach, though outcomes are generally less favourable than for B-cell lymphomas.

  • Upfront autologous stem cell transplant

    Considered in first remission for eligible patients, given relatively poor outcomes with chemotherapy alone in most subtypes.

  • Brentuximab vedotin

    A targeted antibody-drug conjugate for CD30-positive subtypes, including anaplastic large cell lymphoma.

  • Other targeted and novel agents

    Used for relapsed or refractory disease, chosen according to subtype and prior treatment.

  • Clinical trial enrolment

    Often encouraged given the rarity of PTCL and the ongoing need for better treatments across subtypes.

  • Specialist haemato-oncology MDT

    Every case is managed by a commissioned MDT with specific T-cell lymphoma expertise, given the complexity of subtyping and treatment choice.

  • Response assessment imaging

    Interim and end-of-treatment PET-CT to judge response and guide decisions on transplant or further therapy.

  • Supportive and palliative care

    Symptom control, infection prevention and psychological support run alongside active treatment at every stage.

What this guide is based on

The sources behind every claim on this page.

UK national guidance and specialist society standards, current at the time of last review.

Key references

Guidelines and standards we relied on.

A quiet reminder

This guide is for information, not medical advice.

Your haemato-oncology team knows your subtype, staging and fitness for treatment - and can tell you which parts apply to you.

  • NICE. Suspected cancer: recognition and referral (NG12); Non-Hodgkin lymphoma (NG52).

  • British Society for Haematology (BSH). Guidelines on the diagnosis and management of T-cell lymphomas.

  • European Society for Medical Oncology (ESMO). Peripheral T-cell lymphoma clinical practice guidelines.

  • Lymphoma Action. Patient information on peripheral T-cell lymphoma and its subtypes.

Red flags

When to seek urgent attention.

PTCL can move quickly. These are the situations that need same-day or urgent specialist contact.

  • Rapidly progressive lymphadenopathy

    Fast-growing or widespread node enlargement over days to weeks needs urgent haematology referral, not a watch-and-wait approach.

  • Marked B symptoms

    Drenching night sweats, unexplained fever and significant weight loss together are a strong signal for urgent investigation.

  • Marrow failure signs

    Unexplained bruising, bleeding, severe fatigue or recurrent infection may indicate bone marrow involvement.

  • Skin infiltration with systemic illness

    New rashes or plaques alongside systemic symptoms should prompt joint dermatology and haematology assessment.

  • Tumour lysis risk before treatment

    Bulky, fast-growing disease carries a risk of tumour lysis syndrome once chemotherapy starts - needs proactive monitoring.

  • Neutropenic sepsis during treatment

    Fever during chemotherapy is a medical emergency and needs same-day assessment, whatever the time of day.

  • Relapse after transplant

    New or returning symptoms after autologous transplant should prompt prompt reassessment by the treating MDT.

  • Organ compression

    Bulky nodal disease causing breathlessness, swelling or nerve symptoms needs urgent same-week review.

  • Rapid deterioration in known disease

    A sudden change in someone already under haemato-oncology care warrants contacting the treating team the same day.

Living with it

A rare diagnosis, a well-worn specialist pathway.

Four things that make the biggest difference through diagnosis and treatment - the right team, close symptom tracking, an open mind about trials and good peer support.

A quiet reminder

Rare does not mean untreatable.

Specialist centres see enough PTCL to build real expertise, even though it is uncommon in any one local hospital.

  1. 01 Team

    Lean on the specialist MDT

    PTCL is rare enough that ongoing input from a specialist centre, not just a local team, genuinely changes outcomes.

  2. 02 Symptoms

    Track B symptoms closely

    Keep a simple record of fever, sweats and weight - it helps the team judge response and catch relapse early.

  3. 03 Trials

    Ask about clinical trials early

    Because PTCL is rare, trials often offer access to newer agents - it is worth raising at diagnosis, not just at relapse.

  4. 04 Support

    Use lymphoma-specific support

    Charities such as Lymphoma Action offer information and peer support tailored to T-cell lymphomas specifically.

Frequently asked

Everything we get asked about PTCL.

Quick answers on subtypes, diagnosis, transplant and what happens if it comes back.

  • What is peripheral T-cell lymphoma?

    It is a rare, aggressive group of non-Hodgkin lymphomas that develop from mature T-cells. It includes several subtypes, the most common being PTCL-not otherwise specified, alongside angioimmunoblastic T-cell lymphoma and anaplastic large cell lymphoma.

  • Why is it harder to treat than B-cell lymphoma?

    PTCL more often presents at an advanced stage, and as a group it generally has a worse prognosis than B-cell lymphomas, even with similar chemotherapy regimens. This is part of why upfront transplant and clinical trials feature more prominently in its management.

  • What tests are needed to diagnose it?

    A lymph node excision biopsy with detailed immunohistochemistry and molecular studies is essential, given how complex T-cell lymphoma subtyping is. This is usually combined with CT or PET-CT staging and a bone marrow biopsy.

  • What does first-line treatment usually involve?

    Most people start with CHOP-based combination chemotherapy. For eligible patients, an upfront autologous stem cell transplant in first remission is often considered, given relatively poor outcomes with chemotherapy alone.

  • What happens if the lymphoma comes back?

    Relapsed or refractory disease is often treated with novel or targeted agents, such as brentuximab vedotin for CD30-positive subtypes. Clinical trial enrolment is frequently encouraged at this stage, given the rarity of the condition and the need for better treatments.

  • Who manages my care?

    Because PTCL is rare and complex, care is led by a specialist commissioned haemato-oncology multidisciplinary team with specific T-cell lymphoma expertise, rather than by a general local team alone.

Related content

Keep reading.